183 related articles for article (PubMed ID: 37668527)
1. A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.
Shi J; Jiao T; Guo Q; Weng W; Ma L; Zhang Q; Wang L; Zhang J; Chen C; Huang Y; Wang M; Pan R; Tang Y; Hu W; Meng T; Liu SH; Guo J; Kong Y; Meng X
Cancer Res; 2023 Nov; 83(22):3783-3795. PubMed ID: 37668527
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.
Weng W; Meng T; Zhao Q; Shen Y; Fu G; Shi J; Zhang Y; Wang Z; Wang M; Pan R; Ma L; Chen C; Wang L; Zhou B; Zhang H; Pu J; Zhang J; Hu YP; Hua G; Qian Y; Liu SH; Hu W; Meng X
Cancer Discov; 2023 Apr; 13(4):950-973. PubMed ID: 36693125
[TBL] [Abstract][Full Text] [Related]
3. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors.
Kong C; Pu J; Zhao Q; Weng W; Ma L; Qian Y; Hu W; Meng X; Meng T
Mol Cancer Ther; 2023 Oct; 22(10):1128-1143. PubMed ID: 37352387
[TBL] [Abstract][Full Text] [Related]
4. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
5. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
[TBL] [Abstract][Full Text] [Related]
6. Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology.
Ogitani Y; Abe Y; Iguchi T; Yamaguchi J; Terauchi T; Kitamura M; Goto K; Goto M; Oitate M; Yukinaga H; Yabe Y; Nakada T; Masuda T; Morita K; Agatsuma T
Bioorg Med Chem Lett; 2016 Oct; 26(20):5069-5072. PubMed ID: 27599744
[TBL] [Abstract][Full Text] [Related]
7. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates.
Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA
Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728
[TBL] [Abstract][Full Text] [Related]
8. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract][Full Text] [Related]
9. AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X
Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522
[TBL] [Abstract][Full Text] [Related]
10. Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma.
Feng R; Wang Y; Ramachandran V; Ma Q; May MM; Li M; Zhou JX; Xu X; Xu K; Fang S; Xia W; Sui D; Liu H; Gao X; Prieto V; Blacklow SC; Lu M; Lee JE
J Exp Clin Cancer Res; 2020 Dec; 39(1):273. PubMed ID: 33278894
[TBL] [Abstract][Full Text] [Related]
11. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
[TBL] [Abstract][Full Text] [Related]
12. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
13. Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors.
Guo Y; Shen Z; Zhao W; Lu J; Song Y; Shen L; Lu Y; Wu M; Shi Q; Zhuang W; Qiu Y; Sheng J; Zhou Z; Fang L; Che J; Dong X
Adv Sci (Weinh); 2024 Apr; 11(13):e2306309. PubMed ID: 38269648
[TBL] [Abstract][Full Text] [Related]
14. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
Scribner JA; Hicks SW; Sinkevicius KW; Yoder NC; Diedrich G; Brown JG; Lucas J; Fuller ME; Son T; Dastur A; Hooley J; Espelin C; Themeles M; Chen FZ; Li Y; Chiechi M; Lee J; Barat B; Widjaja L; Gorlatov S; Tamura J; Ciccarone V; Ab O; McEachem KA; Koenig S; Westin EH; Moore PA; Chittenden T; Gregory RJ; Bonvini E; Loo D
Mol Cancer Ther; 2022 Jul; 21(7):1047-1059. PubMed ID: 35511740
[TBL] [Abstract][Full Text] [Related]
16. [Development of New ADC Technology with Topoisomerase I Inhibitor].
Agatsuma T
Yakugaku Zasshi; 2017; 137(5):545-550. PubMed ID: 28458286
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
18. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
[TBL] [Abstract][Full Text] [Related]
19. Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform.
Conilh L; Fournet G; Fourmaux E; Murcia A; Matera EL; Joseph B; Dumontet C; Viricel W
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33803327
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
